Sunday, October 2, 2022


Biotechnology News Magazine

Sunny Uberoi Named Chief Communications Officer of Aditxt Therapeutics

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Sunny Uberoi joins Aditxt Therapeutics to raise the company’s profile in advance of initiating its first-in-human clinical trials and support the rapid scaling of AditxtScore, a commercial technology platform designed to provide a personalized, comprehensive profile of the immune system.

Sunny Uberoi will be responsible for leading global corporate communications, investor relations, and government affairs.

“Aditxt is a strong purpose-led brand with an emerging community of stakeholders around the world. To achieve our commitments to growing our brand authentically, we need the right executives to support our mission and business model. Sunny brings a unique combination of senior leadership experience in healthtech, financial services and biopharmaceuticals, and his guidance will be critical to the next phase of growth for our company,” said Amro Albanna, co-founder and CEO of Aditxt. ”

Most recently, Uberoi served as the Vice President of Corporate Affairs for Global Drug Development, Research and Early Development, and Global Product Supply at Bristol Myers Squibb. Uberoi also led communications for S&P Global Market Intelligence, including the asset divesture of J.D. Power. Before that, he was the Head of Corporate Stakeholder Engagement at Deloitte as well as the Head of Global Communications for Consumer Health at Pfizer.

Uberoi earned his bachelor’s degree in Economics from The Manchester Metropolitan University and a Master’s degree in Marketing from The University of Manchester.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine